Matches in SemOpenAlex for { <https://semopenalex.org/work/W2100055125> ?p ?o ?g. }
- W2100055125 abstract "More than 30% of lung cancers arise in patients aged 70 years or more; however, because elderly patients are not considered to tolerate chemotherapy, they are generally excluded from clinical trials and are not considered eligible for aggressive cisplatin-based chemotherapy in clinical practice. The aims of the present study were to test tolerability and activity of weekly vinorelbine in advanced non-small cell lung cancer (NSCLC) patients aged 70 years or more, and to define whether minimum conditions existed for a randomised comparison with best supportive care. The study was designed as a multicentre two-stage phase II trial according to Simon's optimal design: 8 or more responses out of 43 treated patients were expected at the end of the trial. Patients aged 70 years or more were eligible if they had a cytological or histological diagnosis of NSCLC at stage IIIb-IV and a performance status less than or equal to two according to the ECOG scale. Vinorelbine was given intravenously (i.v.) at a dose of 30 mg/m2 every week for 12 doses. As planned, 43 patients entered the study; median age was 73 years (range 70-80); 11 patients were older than 75 years. Median dose-intensity (mg/m2/week) of vinorelbine was 21.2 (range 7.5-30) and was not affected by age of patients. Toxicity was generally mild, mainly haematological and never life-threatening. ECOG performance status improved in 26% of patients; cough and pain improved in more than 40% of patients symptomatic at entry, while dyspnoea improved in 28%; approximately half the patients had a stabilisation of their symptoms. 10 patients (23-95% exact confidence interval (CI): 12-39%) obtained a partial response. Median time to progression was 11 weeks (95% CI 8-30) and median survival 36 weeks (95% CI 28-53). One-year estimated progression-free and overall survival rates are 16% and 36%, respectively. In conclusion, vinorelbine was well tolerated and active in the treatment of elderly NSCLC patients. A phase III trial (ELVIS-Elderly Lung Cancer Vinorelbine Italian Study) comparing best supportive care versus best supportive care plus vinorelbine is now ongoing." @default.
- W2100055125 created "2016-06-24" @default.
- W2100055125 creator A5000640059 @default.
- W2100055125 creator A5001495249 @default.
- W2100055125 creator A5003664573 @default.
- W2100055125 creator A5004329154 @default.
- W2100055125 creator A5015952023 @default.
- W2100055125 creator A5016655393 @default.
- W2100055125 creator A5023215623 @default.
- W2100055125 creator A5032078755 @default.
- W2100055125 creator A5033454821 @default.
- W2100055125 creator A5036093050 @default.
- W2100055125 creator A5045384053 @default.
- W2100055125 creator A5046785006 @default.
- W2100055125 creator A5052325028 @default.
- W2100055125 creator A5073420952 @default.
- W2100055125 creator A5085096826 @default.
- W2100055125 date "1997-03-01" @default.
- W2100055125 modified "2023-10-18" @default.
- W2100055125 title "Vinorelbine is well tolerated and active in the treatment of elderly patients with advanced non-small cell lung cancer. A two-stage phase II study" @default.
- W2100055125 cites W191227362 @default.
- W2100055125 cites W1964842293 @default.
- W2100055125 cites W1979300931 @default.
- W2100055125 cites W1995686464 @default.
- W2100055125 cites W2011797387 @default.
- W2100055125 cites W2029409133 @default.
- W2100055125 cites W2070577869 @default.
- W2100055125 cites W2129793485 @default.
- W2100055125 cites W2133514662 @default.
- W2100055125 cites W2157784057 @default.
- W2100055125 cites W2167805334 @default.
- W2100055125 cites W2256453366 @default.
- W2100055125 cites W2328859529 @default.
- W2100055125 cites W2408247009 @default.
- W2100055125 cites W2410530972 @default.
- W2100055125 cites W2504684570 @default.
- W2100055125 cites W3166029991 @default.
- W2100055125 cites W368475356 @default.
- W2100055125 doi "https://doi.org/10.1016/s0959-8049(97)89011-9" @default.
- W2100055125 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/9155522" @default.
- W2100055125 hasPublicationYear "1997" @default.
- W2100055125 type Work @default.
- W2100055125 sameAs 2100055125 @default.
- W2100055125 citedByCount "91" @default.
- W2100055125 countsByYear W21000551252012 @default.
- W2100055125 countsByYear W21000551252013 @default.
- W2100055125 countsByYear W21000551252015 @default.
- W2100055125 countsByYear W21000551252016 @default.
- W2100055125 crossrefType "journal-article" @default.
- W2100055125 hasAuthorship W2100055125A5000640059 @default.
- W2100055125 hasAuthorship W2100055125A5001495249 @default.
- W2100055125 hasAuthorship W2100055125A5003664573 @default.
- W2100055125 hasAuthorship W2100055125A5004329154 @default.
- W2100055125 hasAuthorship W2100055125A5015952023 @default.
- W2100055125 hasAuthorship W2100055125A5016655393 @default.
- W2100055125 hasAuthorship W2100055125A5023215623 @default.
- W2100055125 hasAuthorship W2100055125A5032078755 @default.
- W2100055125 hasAuthorship W2100055125A5033454821 @default.
- W2100055125 hasAuthorship W2100055125A5036093050 @default.
- W2100055125 hasAuthorship W2100055125A5045384053 @default.
- W2100055125 hasAuthorship W2100055125A5046785006 @default.
- W2100055125 hasAuthorship W2100055125A5052325028 @default.
- W2100055125 hasAuthorship W2100055125A5073420952 @default.
- W2100055125 hasAuthorship W2100055125A5085096826 @default.
- W2100055125 hasConcept C121608353 @default.
- W2100055125 hasConcept C126322002 @default.
- W2100055125 hasConcept C141071460 @default.
- W2100055125 hasConcept C143998085 @default.
- W2100055125 hasConcept C146357865 @default.
- W2100055125 hasConcept C151730666 @default.
- W2100055125 hasConcept C197934379 @default.
- W2100055125 hasConcept C2776256026 @default.
- W2100055125 hasConcept C2776694085 @default.
- W2100055125 hasConcept C2776907518 @default.
- W2100055125 hasConcept C2778239845 @default.
- W2100055125 hasConcept C2778375690 @default.
- W2100055125 hasConcept C2780350996 @default.
- W2100055125 hasConcept C31760486 @default.
- W2100055125 hasConcept C535046627 @default.
- W2100055125 hasConcept C71924100 @default.
- W2100055125 hasConcept C86803240 @default.
- W2100055125 hasConceptScore W2100055125C121608353 @default.
- W2100055125 hasConceptScore W2100055125C126322002 @default.
- W2100055125 hasConceptScore W2100055125C141071460 @default.
- W2100055125 hasConceptScore W2100055125C143998085 @default.
- W2100055125 hasConceptScore W2100055125C146357865 @default.
- W2100055125 hasConceptScore W2100055125C151730666 @default.
- W2100055125 hasConceptScore W2100055125C197934379 @default.
- W2100055125 hasConceptScore W2100055125C2776256026 @default.
- W2100055125 hasConceptScore W2100055125C2776694085 @default.
- W2100055125 hasConceptScore W2100055125C2776907518 @default.
- W2100055125 hasConceptScore W2100055125C2778239845 @default.
- W2100055125 hasConceptScore W2100055125C2778375690 @default.
- W2100055125 hasConceptScore W2100055125C2780350996 @default.
- W2100055125 hasConceptScore W2100055125C31760486 @default.
- W2100055125 hasConceptScore W2100055125C535046627 @default.
- W2100055125 hasConceptScore W2100055125C71924100 @default.
- W2100055125 hasConceptScore W2100055125C86803240 @default.
- W2100055125 hasLocation W21000551251 @default.
- W2100055125 hasLocation W21000551252 @default.